Seelos Therapeutics Shares Slide Premarket on SLS-002 Study Shortfall >SEEL

By Colin Kellaher

Seelos Therapeutics shares tumbled in premarket trading Wednesday after the clinical-stage biopharmaceutical company said a Phase 2 study of its SLS-002 depression drug candidate missed its key goal due to an shortfall in enrollment.

The New York company said SLS-002 showed clinically meaningful treatment effects across multiple…